THE NEUROCARE™NC2000 NMES

& ITS TREATMENT PROGRAMME©
FDA & CE MARKED

> SAFE NON INVASIVE

> PROMOTE THE CURING OF RECALCITRANT ULCERS

> EXPEDITE DELIVERY OF THE ANTIBIOTICS THROUGH WOUND
SITE

> PREVENT POSSIBLE AMPUTATION

> SUBSTANTIALLY REDUCE TREATMENT TIMESCALES

> THEREBY GREATLY IMPROVING PATIENT WELL-BEING

> CONSIDERABLE SAVINGS TO HOSPITALS AND CLINICS

ADDITIONAL PATIENT BENEFITS INCLUDE

> REVERSING NEUROPATHY

> MINIMISING OEDEMA

> REDUCING PAIN

Used in CLINICS, HOSPITALS & HOME under medical supervision for the following types of chronic ulcers:

> Arterial ulcers

> Diabetic ulcers

> Stage III (defects extending into stage IV
the muscle) or (defects extending into the
the bone or the joint) pressure ulcers or

> Venous stasis ulcers

AND

> Incisions after surgery

> Pressure Ulcers

Fotolia_21621512_S[1] circulatory sitting man

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.


Get Flash Player